Andrew Cutler, MD
Internal Medicine · Watertown, MANPI 1437159720
Payments from drug & device makers
Across 492 payments — averaging $146.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tris Pharma Inc$46K
- AbbVie$15K
- Neurocrine Biosciences, Inc.$3K
- AstraZeneca$1K
- Novo Nordisk$868
- Teva Pharmaceuticals USA, Inc.$801
- plus $5K from 32 others
What the payments were for
- Consulting fees$16,85023%
- Speaking & faculty fees$40,89057%
- Travel & lodging$4,7177%
- Food & beverage$9,73013%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tris Pharma Inc | 57 | $45,867 |
| AbbVie(2 entities) | 28 | $15,120 |
| Neurocrine Biosciences, Inc. | 4 | $2,680 |
| AstraZeneca | 82 | $1,496 |
| Novo Nordisk | 44 | $868 |
| Teva Pharmaceuticals USA, Inc. | 17 | $801 |
| Lilly USA, LLC | 38 | $634 |
| Pfizer | 32 | $600 |
| Amgen | 22 | $512 |
| Johnson & Johnson | 24 | $499 |
| Boehringer Ingelheim | 20 | $466 |
| GSK | 19 | $357 |
| Merck | 19 | $323 |
| Axsome Therapeutics, Inc. | 2 | $292 |
| Astellas Pharma US Inc | 8 | $187 |
| Novartis | 11 | $176 |
| E.r. Squibb & Sons, L.L.C. | 9 | $172 |
| Janssen Scientific Affairs, LLC | 3 | $126 |
| Amarin Pharma, Inc. | 6 | $111 |
| Idorsia Pharmaceuticals US Inc | 5 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $89 |
| Tolmar, Inc. | 5 | $82 |
| Endo Pharmaceuticals Inc. | 4 | $76 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $74 |
| Exact Sciences | 3 | $68 |
| Abbott | 3 | $65 |
| Alkermes, Inc. | 2 | $63 |
| Almatica Pharma LLC | 2 | $58 |
| Sage Therapeutics, LLC | 1 | $54 |
| Sanofi-aventis U.S. LLC | 2 | $48 |
| Sanofi Pasteur Inc. | 2 | $38 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Halozyme Inc | 1 | $33 |
| Acerus Pharmaceuticals Corporation | 2 | $25 |
| Antares Pharma, Inc. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Dynavax Technologies Corporation | 1 | $18 |
| Bausch Health US, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Quillichew ER$45,472
- Dyanavel XR$45,472
- Quillivant$44,172
- VRAYLAR$8,240
- Quillivant XR$1,300
- Auvelity$244
- Austedo XR$239
- AUSTEDO$140
How this compares
$72,271 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 120 | $134,497 |
| JardianceEmpagliflozin | 70 | $88,457 |
| TrulicityDulaglutide | 41 | $57,006 |
| OzempicSemaglutide | 50 | $55,293 |
| FarxigaDapagliflozin Propanediol | 58 | $53,060 |
| MounjaroTirzepatide | 25 | $24,423 |
| XareltoRivaroxaban | 18 | $24,153 |
| JanuviaSitagliptin Phosphate | 14 | $22,148 |
| EntrestoSacubitril/Valsartan | 17 | $15,389 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $8,286 |
| RestasisCyclosporine | 12 | $8,025 |
| Atorvastatin Calcium | 464 | $7,899 |
| Metoprolol Succinate | 224 | $4,869 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 85 | $3,423 |
| Rosuvastatin Calcium | 111 | $3,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $600 | $134,497120 claims |
| Boehringer IngelheimJardiance | $466 | $88,45770 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $634 | $81,42966 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,496 | $61,34570 claims |
| Novo NordiskOzempic | $868 | $55,29350 claims |
| Johnson & JohnsonXarelto | $499 | $24,15318 claims |
| MerckJanuvia | $323 | $22,14814 claims |
| NovartisEntresto | $176 | $15,38917 claims |
| AbbVieRestasis | $15,120 | $8,02512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Watertown
- Noopur RajeBoston$19.9M
- Michael McCartneyNewburyport$17.6M
- Rebecca HeistBoston$17.4M
- Richard PlattBoston$13.5M
- Ryan CorcoranBoston$11.4M
- Joyce LiuCharlestown$10.3M
- Elizabeth LeeBoston$9.8M
- Adnan DahdulSpringfield$8.8M
- Ryan SullivanCambridge$8.5M
- Xiuning leBoston$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.